Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

clinical trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT03959085

P6099clinical trial phasephase III clinical trialQ42824827
P582end time2027-05-31
P4135maximum age25
P1050medical conditionleukemiaQ29496
P1132number of participants3698
P4844research interventiondoxorubicinQ18936
folic acidQ127060
cytarabineQ180983
2-aminopurineQ209313
6-thioguanineQ385347
(RS)-cyclophosphamideQ408524
calcium oxalateQ412399
methylprednisoloneQ417222
mercaptopurineQ418529
asparaginaseQ421534
leucovorin calciumQ27077063
prednisolone acetateQ27108063
methylprednisolone hemisuccinateQ27262132
prednisolone 21-phosphateQ27266327
CaelyxQ29004943
pegaspargaseQ7160547
prednisoloneQ11426176
P6153research siteVanderbilt UniversityQ29052
Yale UniversityQ49112
West Virginia UniversityQ115376
University of ChicagoQ131252
University of RochesterQ149990
University of North Carolina at Chapel HillQ192334
Johns Hopkins UniversityQ193727
University of PittsburghQ235034
University of MinnesotaQ238101
Oregon Health & Science UniversityQ282097
Georgetown UniversityQ333886
Wake Forest UniversityQ392667
University of MiamiQ738258
Stony Brook UniversityQ969850
University of Illinois Urbana–ChampaignQ457281
Southern Illinois University EdwardsvilleQ519349
McMaster UniversityQ632891
Cedars-Sinai Medical CenterQ1052562
Loma Linda UniversityQ1057447
Mayo ClinicQ1130172
Dana–Farber Cancer InstituteQ1159198
East Carolina UniversityQ1277776
Indiana University – Purdue University IndianapolisQ1433199
University of Colorado DenverQ1468161
Mount Sinai HospitalQ1476505
Memorial Sloan Kettering Cancer CenterQ1808012
New York Medical CollegeQ4115972
Cleveland ClinicQ4117596
Children's Hospital of PhiladelphiaQ4569202
Arkansas Children's HospitalQ4791755
Arnold Palmer Hospital for ChildrenQ4795196
Baystate Medical CenterQ4874851
Children's Hospital of Orange CountyQ5098129
Children's Hospital of The King's DaughtersQ5098131
Children's National HospitalQ5098193
Cincinnati Children's Hospital Medical CenterQ5120231
Connecticut Children's Medical CenterQ5161492
Dayton Children's HospitalQ5243510
Eastern Maine Medical CenterQ5330270
Augusta UniversityQ5547686
Loyola University Medical CenterQ6694611
Maimonides Medical CenterQ6735870
IWK Health CentreQ14875689
Memorial Health University Medical CenterQ30253539
Cook Children's Medical CenterQ30254344
Duke University Medical CenterQ30279912
Atrium Health Navicent The Medical CenterQ6806287
Miami Children's HospitalQ6827285
Miller Children's HospitalQ6859100
Mission Health SystemQ6878595
Morristown Medical CenterQ6914126
Newark Beth Israel Medical CenterQ7016630
Roswell Park Comprehensive Cancer CenterQ7370121
Santa Barbara Cottage HospitalQ7419217
Tampa General HospitalQ7681712
University Medical Center of Southern NevadaQ7894830
University of Mississippi Medical CenterQ7895818
University of Nebraska Medical CenterQ7895888
University of Oklahoma Health Sciences CenterQ7896014
Washington University School of MedicineQ7972509
Helen DeVos Children's HospitalQ14716129
P580start time2019-11-23
P8363study typeinterventional studyQ78089383
P1476titleA Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Search more.